Exelixis Inc (EXEL) Com Stk Usd0.001
$0.39
(2.41%)
- Add to watchlist
- This stock can be held in a
$0.39
(2.41%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.39
(2.41%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.
Contact details
Important dates
General stock information
- Short code:
- EXEL
- ISIN:
- US30161Q1040
- Market cap:
- $5.12 billion
- Shares in issue:
- 316.40 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.